المؤلفون: McFarlane, Joshua J., Kochenderfer, Mark D., Olsen, Mark R., Bauer, Todd M., Molina, Ana, Hauke, Ralph J., Reeves, James A., Babu, Sunil, Van Veldhuizen, Peter, Somer, Bradley, Gunuganti, Vijay, Schnadig, Ian, George, Saby, Page, Ray D., Arrowsmith, Edward, Jain, Rohit K., Zhang, Joshua, McHenry, M. Brent, Johansen, Jennifer L., Vogelzang, Nicholas J.

المساهمون: Bristol-Myers Squibb Company, Daiichi-Sankyo, Medpacto, Incyte, Mirati Therapeutics, MedImmune, AbbVie, AstraZeneca, MabVax, Stemline Therapeutics, Merck, Lilly, GlaxoSmithKline, Novartis, Genentech, Deciphera, Merrimack, Immunogen, Millennium, Phosplatin Therapeutics, Calithera Biosciences, Kolltan Pharmaceuticals, Principa Biopharma, Peloton Pharmaceuticals, Immunocore, Roche, Aileron Therapeutics, Amgen, Onyx, Sanofi, Boehringer Ingelheim, Astellas Pharma, Five Prime Therapeutics, Jacobio, Top Alliance BioScience, Janssen, Clovis Oncology, Takeda, Karyopharm Therapeutics, Foundation Medicine, ARMO Biosciences, Pfizer, Loxo, Sarah Cannon Research Institute, Eli Lilly, Tesaro, TG Therapeutics, Celgene, BMS, Boston Biomedical Inc, Novocure, Guardant Health, Acerta Pharma, Rhizen Pharmaceuticals, Takeda Pharmaceuticals, Onconova Therapeutics, CTI Biopharma, Bayer, Corvus, Acceleron, Agensys, Eisai

المصدر: Clinical Genitourinary Cancer ; volume 18, issue 6, page 469-476.e4 ; ISSN 1558-7673

مصطلحات موضوعية: Urology, Oncology

الإتاحة: https://doi.org/10.1016/j.clgc.2020.06.002Test
https://api.elsevier.com/content/article/PII:S1558767320301415?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1558767320301415?httpAccept=text/plainTest

المؤلفون: Vogelzang, Nicholas J., Olsen, Mark R., McFarlane, Joshua J., Arrowsmith, Edward, Bauer, Todd M., Jain, Rohit K., Somer, Bradley, Lam, Elaine T., Kochenderfer, Mark D., Molina, Ana, Doshi, Gurjyot, Lingerfelt, Brian, Hauke, Ralph J., Gunuganti, Vijay, Schnadig, Ian, Van Veldhuizen, Peter, Fleming, Mark, Galamaga, Robert, Gupta, Mukul, Hool, Hugo, Hutson, Thomas, Zhang, Joshua, McHenry, M. Brent, Johansen, Jennifer L., Tykodi, Scott S.

المساهمون: Bristol-Myers Squibb Company, BMS, Daiichi-Sankyo, Medpacto, Incyte, Mirati Therapeutics, MedImmune, AbbVie, AstraZeneca, MabVax, Stemline Therapeutics, Merck, Lilly, GlaxoSmithKline, Novartis, Genentech, Deciphera, Merrimack, Immunogen, Millennium, Phosplatin Therapeutics, Calithera Biosciences, Kolltan Pharmaceuticals, Principa Biopharma, Peleton, Immunocore, Roche, Aileron Therapeutics, Amgen, Onyx, Sanofi, Boehringer-Ingelheim, Astellas Pharma, Five Prime Therapeutics, Jacobio, Top Alliance BioScience, Janssen, Clovis Oncology, Takeda, Karyopharm Therapeutics, Foundation Medicine, ARMO Biosciences, Leap Therapeutics, Ignyta, Moderna Therapeutics, Pfizer, Bristol-Myers Squibb

المصدر: Clinical Genitourinary Cancer ; volume 18, issue 6, page 461-468.e3 ; ISSN 1558-7673

مصطلحات موضوعية: Urology, Oncology

الإتاحة: https://doi.org/10.1016/j.clgc.2020.05.006Test
https://api.elsevier.com/content/article/PII:S155876732030104X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S155876732030104X?httpAccept=text/plainTest